Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Darolutamide by Orion for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Darolutamide is under clinical development by Orion and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Tasipimidine by Orion for Unspecified Psychiatric Disorders: Likelihood of Approval
Tasipimidine is under clinical development by Orion and currently in Phase I for Unspecified Psychiatric Disorders. According to GlobalData, Phase...
Darolutamide by Orion for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Darolutamide is under clinical development by Orion and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
AUR-109 by Orion for Pulmonary Fibrosis: Likelihood of Approval
AUR-109 is under clinical development by Orion and currently in Phase II for Pulmonary Fibrosis. According to GlobalData, Phase II...
AUR-109 by Orion for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
AUR-109 is under clinical development by Orion and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to...
AUR-109 by Orion for Liver Cancer: Likelihood of Approval
AUR-109 is under clinical development by Orion and currently in Phase II for Liver Cancer. According to GlobalData, Phase II...
AUR-109 by Orion for Ovarian Cancer: Likelihood of Approval
AUR-109 is under clinical development by Orion and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
AUR-109 by Orion for Lung Cancer: Likelihood of Approval
AUR-109 is under clinical development by Orion and currently in Phase II for Lung Cancer. According to GlobalData, Phase II...
AUR-109 by Orion for Breast Cancer: Likelihood of Approval
AUR-109 is under clinical development by Orion and currently in Phase II for Breast Cancer. According to GlobalData, Phase II...
ODM-212 by Orion for Solid Tumor: Likelihood of Approval
ODM-212 is under clinical development by Orion and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Levosimendan by Orion for Subarachnoid Hemorrhage: Likelihood of Approval
Levosimendan is under clinical development by Orion and currently in Phase II for Subarachnoid Hemorrhage. According to GlobalData, Phase II...